Sign in to view content

Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials

Katherine E Talcott, MD

Video
Published 2021

Related

Amine Oxidase Copper-Containing 3 Inhibitor (BI 1467335) in Non-Proliferative Diabetic Retinopathy: Double-Masked, Randomized, Phase IIa Study (ROBIN)
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2021
Episode 14: Plasma VEGF Levels After Anti-VEGF Injections (DRCR protocol T) with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
New Biosimilar Bevacizumab and Ranibizumab for Retinal Diseases
Alay S. Banker, MD
Annual Meeting Talks
2018

Category: Diabetic Retinopathy

See more